Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company's strategic focus on NDA filing, market access, and commercialization planning for lorundrostat indicates a positive outlook. The Q&A reveals confidence in payer engagement and differentiation strategies, despite some uncertainties in commercial specifics. The positive clinical data and emphasis on significant unmet needs in hypertension further support a positive sentiment. However, the lack of specific details in some responses and the short duration of the Phase II OSA study may temper expectations slightly, but overall, the sentiment remains positive.
Key Financial Performance
Cash, Cash Equivalents, and Investments $656.6 million as of December 31, 2025, compared to $198.2 million as of December 31, 2024. This increase is attributed to funding activities that will support clinical trials, regulatory activities, and corporate operations into 2028.
R&D Expenses (Annual) $132 million for the year ended December 31, 2025, compared to $168.6 million for the year ended December 31, 2024. This 21.7% decrease was primarily driven by a $49.3 million reduction in preclinical and clinical costs due to the conclusion of the lorundrostat pivotal program in Q2 2025. However, it was partially offset by a $9.9 million increase in compensation expenses and a $3 million increase in clinical supply, manufacturing, and regulatory costs.
R&D Expenses (Quarterly) $24.4 million for the quarter ended December 31, 2025, compared to $44.6 million for the quarter ended December 31, 2024. This 45.3% decrease was primarily due to the conclusion of the lorundrostat pivotal program.
G&A Expenses (Annual) $38.6 million for the year ended December 31, 2025, compared to $23.8 million for the year ended December 31, 2024. This 62.2% increase was primarily due to an $8.9 million rise in compensation expenses driven by headcount growth, higher salaries, accrued bonuses, and increased stock-based compensation, as well as a $5.3 million increase in professional fees.
G&A Expenses (Quarterly) $13.9 million for the quarter ended December 31, 2025, compared to $7.2 million for the quarter ended December 31, 2024. This 93.1% increase was driven by similar factors as the annual increase, including higher compensation expenses and professional fees.
Total Other Income (Annual) $16 million for the year ended December 31, 2025, compared to $14.6 million for the year ended December 31, 2024. This 9.6% increase was primarily due to higher interest earned on investments in money market funds and U.S. treasuries, resulting from higher average cash balances.
Total Other Income (Quarterly) $6 million for the quarter ended December 31, 2025, compared to $2.8 million for the quarter ended December 31, 2024. This 114.3% increase was also due to higher interest earned on investments.
Net Loss (Annual) $154.7 million for the year ended December 31, 2025, compared to $177.8 million for the year ended December 31, 2024. This 13% decrease was primarily due to reduced R&D expenses.
Net Loss (Quarterly) $32.2 million for the quarter ended December 31, 2025, compared to $48.9 million for the quarter ended December 31, 2024. This 34.2% decrease was also primarily due to reduced R&D expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FDA acceptance of NDA for lorundrostat: The FDA has accepted the NDA for lorundrostat for treating adult patients with hypertension in combination with other antihypertensive drugs. The PDUFA target action date is December 22, 2026.
Clinical trial results for lorundrostat: Five positive clinical trials demonstrated clinically meaningful blood pressure reduction, 24-hour control, and a favorable safety profile. Trials include Launch-HTN, Advance-HTN, Explore-CKD, and Transform-HTN.
Explore-OSA trial results: The trial showed clinically meaningful reductions in blood pressure and a favorable safety profile in patients with moderate to severe obstructive sleep apnea and hypertension, despite not meeting the primary endpoint.
Market access planning for lorundrostat: Efforts include payer engagement, increased peer-reviewed publications, presence at scientific meetings, and an expanded team of medical science liaisons to support data dissemination.
Financial position: Cash, cash equivalents, and investments totaled $656.6 million as of December 31, 2025, sufficient to fund operations into 2028.
R&D expenses: R&D expenses decreased to $132 million in 2025 from $168.6 million in 2024, primarily due to the conclusion of lorundrostat pivotal program.
G&A expenses: G&A expenses increased to $38.6 million in 2025 from $23.8 million in 2024, driven by headcount growth, higher salaries, and professional fees.
Focus on lorundrostat development: The company is focused on extending lorundrostat's profile into hypertension with comorbid conditions and exploring further clinical development for other potential indications.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval Uncertainty: The FDA's acceptance of the NDA for lorundrostat is a positive step, but the final approval is not guaranteed. The PDUFA target action date is December 22, 2026, and any delays or rejections could impact the company's strategic plans and financial performance.
Market Access and Payer Engagement: The company is actively working on market access planning and payer engagement to ensure the value proposition of lorundrostat is understood. However, challenges in achieving favorable reimbursement terms or market acceptance could hinder the product's commercial success.
Clinical Trial Outcomes: While lorundrostat showed positive results in several trials, the Explore-OSA trial did not demonstrate a clinically meaningful difference on its primary endpoint. This raises concerns about its efficacy in certain patient populations, which could limit its market potential.
Financial Sustainability: The company reported a net loss of $154.7 million for 2025, although it has sufficient cash reserves to fund operations into 2028. Continued financial losses could pose a risk if revenue generation from lorundrostat or other products is delayed.
Operational Costs: Increased R&D and G&A expenses, driven by headcount growth, higher salaries, and stock-based compensation, could strain financial resources if not offset by revenue growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
FDA's acceptance of the NDA for lorundrostat: The FDA has accepted the NDA for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs. The PDUFA target action date is set for December 22, 2026.
Market access planning and payer engagement for lorundrostat: The company has initiated market access planning and payer engagement to ensure the value proposition of lorundrostat is understood and appreciated. This includes increased peer-reviewed publications, a larger presence at scientific meetings, and an expanded team of field-based medical science liaisons.
Exploratory trial results for lorundrostat in obstructive sleep apnea and hypertension: The exploratory trial, Explore-OSA, showed clinically meaningful reductions in blood pressure and a favorable safety profile in a high-risk population with difficult-to-control hypertension. Further analysis of other endpoints is ongoing and will be reported in future publications or medical meetings.
Future clinical development for lorundrostat: The company is evaluating further clinical development for lorundrostat in comorbidities and other potential indications.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the company's plans to optimize the success of lorundrostat's launch given its competitor's earlier launch?
A:The company is observing AstraZeneca's potential launch in Q2 to understand their pricing and market approach. They believe the market is large enough for two novel therapeutics and are confident in lorundrostat's best-in-class profile. They are targeting third-line or later use, focusing on resistant hypertension patients with comorbidities, and leveraging their comprehensive data set to demonstrate safety and efficacy.
Q:What are the company's thoughts on the Phase II OSA study design and its impact on results?
A:The company acknowledges the study's short duration (4 weeks) and the inclusion of CPAP/PAP use may have limited its ability to show benefit in the AHI primary endpoint. They believe the study population's severe obesity and high AHI levels may have also influenced results. They emphasize the study's importance in demonstrating lorundrostat's safety and efficacy in high-risk patients and its potential to reduce cardiovascular risk.
Q:What commercial capabilities is the company building ahead of the PDUFA date?
A:The company is making targeted investments, including payer dialogues, expanding medical affairs capabilities, and increasing their MSL team. They aim to ensure rapid uptake upon approval and believe these efforts will also support partnership discussions. They are not disclosing specific commercial team sizes but are preparing for a potential launch.
Q:What is the company's approach to differentiating lorundrostat's market strategy from AstraZeneca's?
A:The company is focusing on third-line or later use, targeting 60,000 physicians responsible for half of third-line prescriptions. They are leveraging their comprehensive data set to identify subsegments of physicians treating specific hypertension types with comorbidities. They are not disclosing specific commercial strategies but aim for rapid uptake in resistant hypertension and third-line use.
Q:How does the company view the PDUFA date as a derisking event?
A:The company sees the PDUFA date as a significant derisking milestone, adding value to lorundrostat. They believe each step, from clinical trial results to NDA submission and acceptance, has progressively derisked the molecule and increased its value.
Q:What are the company's payer access strategies and confidence in coverage?
A:The company is engaging with payers through pre-approval information exchange discussions and believes lorundrostat's value proposition resonates with payers, particularly for resistant hypertension. They are confident in achieving favorable access with appropriate pricing and rebate strategies.
Q:What are the company's plans for ex-U.S. regulatory submissions and partnerships?
A:The company is evaluating complexities like MFN and tariffs for ex-U.S. submissions. Partnerships may play a role in co-promotion or co-development. They are considering whether to introduce lorundrostat as a monotherapy or in fixed-dose combinations and will communicate plans once finalized.
Q:What is the company's pricing strategy for lorundrostat?
A:The company is considering a pricing strategy similar to SGLT2-branded drugs or Entresto, with a focus on fourth-line use initially. They aim to expand to third-line use with experience and demand. Pricing specifics, including rebates, are not yet disclosed.
Q:What are the company's plans for leveraging data from Explore-CKD and Explore-OSA studies?
A:The company plans to include Explore-CKD data in the NDA application and use it to inform prescribers. Explore-OSA data will not be part of the initial NDA but will be used for medical meetings, publications, and MSL team communications to inform the medical community.
Q:What other comorbidities is the company exploring for lorundrostat?
A:The company is exploring aldosterone-driven conditions like CKD, OSA, and heart failure. They are also considering other indications where dysregulated aldosterone plays a significant role. Some indications may be pursued independently, while others may involve partnerships.
Q:What is the company's target prescriber base for lorundrostat?
A:The company is targeting 60,000 physicians responsible for half of third-line prescriptions, with a 60-40 split between primary care and specialists (mainly cardiologists). They are also focusing on prescribers managing resistant hypertension with comorbidities.
Q:What role does the company see for direct-to-consumer marketing?
A:The company has not finalized its consumer strategy but aims to educate patients on the importance of blood pressure control and the benefits of lorundrostat, particularly for those with overlapping comorbidities.
Q:What are the company's plans for partnerships and deal structuring?
A:The company seeks a partner that shares their vision for lorundrostat as a best-in-class aldosterone synthase inhibitor. They aim to maximize value through co-development and address complexities in ex-U.S. markets. They are open to creative deal structures that support these goals.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers for the commercial team size, details on pricing and rebate strategies, and exact plans for ex-U.S. regulatory submissions. They also used vague language regarding the timing and structure of potential partnerships, as well as the role of direct-to-consumer marketing.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AHI blood
AHI trial
Advisors conference
CKD label
FDA PDUFA
FDA acceptance
Form today
Full Conference
Index AHI
Instructions conference
NDA Launch
NDA lorundrostat
OSA week
PDUFA action
QA filing
States death
Therapeutics Full
acceptance FDA
acceptance NDA
action date
activity uptake
adult patient
afternoon close
aldosterone dysregulation
aldosterone research
aldosterone week
analysis Lorundrostat
analysis endpoint
analysis period
apnea Index
arm analysis
body mass
close market
combination drug
communication effort
comorbidities indication
completion trial
hypertension patient
need hypertension
participant
safety profile
therapy
trial Explore
MLYS Transcript
Mineralys Therapeutics, Inc. (MLYS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-11
Mineralys Therapeutics, Inc. (MLYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Mineralys Therapeutics, Inc. (MLYS) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call summary shows positive financial performance with revenue and net income growth, but lacks discussion on strategic initiatives or operational updates. The Q&A section provided no additional insights or concerns. The absence of strategic updates or shareholder returns, combined with positive but not exceptional financials, suggests a neutral sentiment. Without market cap data, the stock's potential reaction is uncertain, but likely minimal.
Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call Transcript
Positive3-12
The company's strategic focus on NDA filing, market access, and commercialization planning for lorundrostat indicates a positive outlook. The Q&A reveals confidence in payer engagement and differentiation strategies, despite some uncertainties in commercial specifics. The positive clinical data and emphasis on significant unmet needs in hypertension further support a positive sentiment. However, the lack of specific details in some responses and the short duration of the Phase II OSA study may temper expectations slightly, but overall, the sentiment remains positive.
MLYS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
